国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2014年
6期
1020-1022
,共3页
黄晓燕%叶亲颖%黄玉银%邓小宁
黃曉燕%葉親穎%黃玉銀%鄧小寧
황효연%협친영%황옥은%산소저
弥漫型%糖尿病黄斑水肿%全视网膜光凝%曲安奈德后Tenon's囊下注射%疗效
瀰漫型%糖尿病黃斑水腫%全視網膜光凝%麯安奈德後Tenon's囊下註射%療效
미만형%당뇨병황반수종%전시망막광응%곡안내덕후Tenon's낭하주사%료효
diffuse%diabetic macular edema%panretinal photocoagulation%posterior sub - Tenon's triamcinolone acetonide injection%curative effect
目的:研究弥漫型糖尿病黄斑水肿( DME )患者全视网膜光凝( PRP)前,予以TA(曲安奈德注射后Tenon's囊下)治疗的临床效果。<br> 方法:回顾分析我院2008-10/2012-05以来,于我科治疗的96例96眼弥漫型DME患者临床资料,依据治疗方式将其分为研究组与对照组,每组48例48眼,对照组仅予以PRP治疗,研究组PRP 1 wk前,予以TA治疗,在6 mo后对比两组BCVA(最佳的矫正视力)及视网膜厚度改变情况,对两组眼压变化予以分析。<br> 结果:经治疗后,两组6 mo随访发现,对照组同治疗前相较,其BCVA呈降低表现,研究组呈升高表现,两组具有明显差异(P<0.05),并且在随访期内,两组患者眼压均在正常范围内波动变化,不具差异(P>0.05),研究组黄斑中心凹厚度降低9.6μm,对照组增高31.9μm,呈明显差异( P<0.05),研究组旁中心凹厚度降低5.0μm,对照组增加22-1μm,呈明显差异,研究组中心凹周边厚度增加0-4μm,对照组增加19.4μm,不具差异(P>0.05)。<br> 结论:弥漫型DME患者PRP前,予以TA治疗,安全有效,并且优于单纯进行PRP治疗,可以在基层医院推广实施。
目的:研究瀰漫型糖尿病黃斑水腫( DME )患者全視網膜光凝( PRP)前,予以TA(麯安奈德註射後Tenon's囊下)治療的臨床效果。<br> 方法:迴顧分析我院2008-10/2012-05以來,于我科治療的96例96眼瀰漫型DME患者臨床資料,依據治療方式將其分為研究組與對照組,每組48例48眼,對照組僅予以PRP治療,研究組PRP 1 wk前,予以TA治療,在6 mo後對比兩組BCVA(最佳的矯正視力)及視網膜厚度改變情況,對兩組眼壓變化予以分析。<br> 結果:經治療後,兩組6 mo隨訪髮現,對照組同治療前相較,其BCVA呈降低錶現,研究組呈升高錶現,兩組具有明顯差異(P<0.05),併且在隨訪期內,兩組患者眼壓均在正常範圍內波動變化,不具差異(P>0.05),研究組黃斑中心凹厚度降低9.6μm,對照組增高31.9μm,呈明顯差異( P<0.05),研究組徬中心凹厚度降低5.0μm,對照組增加22-1μm,呈明顯差異,研究組中心凹週邊厚度增加0-4μm,對照組增加19.4μm,不具差異(P>0.05)。<br> 結論:瀰漫型DME患者PRP前,予以TA治療,安全有效,併且優于單純進行PRP治療,可以在基層醫院推廣實施。
목적:연구미만형당뇨병황반수종( DME )환자전시망막광응( PRP)전,여이TA(곡안내덕주사후Tenon's낭하)치료적림상효과。<br> 방법:회고분석아원2008-10/2012-05이래,우아과치료적96례96안미만형DME환자림상자료,의거치료방식장기분위연구조여대조조,매조48례48안,대조조부여이PRP치료,연구조PRP 1 wk전,여이TA치료,재6 mo후대비량조BCVA(최가적교정시력)급시망막후도개변정황,대량조안압변화여이분석。<br> 결과:경치료후,량조6 mo수방발현,대조조동치료전상교,기BCVA정강저표현,연구조정승고표현,량조구유명현차이(P<0.05),병차재수방기내,량조환자안압균재정상범위내파동변화,불구차이(P>0.05),연구조황반중심요후도강저9.6μm,대조조증고31.9μm,정명현차이( P<0.05),연구조방중심요후도강저5.0μm,대조조증가22-1μm,정명현차이,연구조중심요주변후도증가0-4μm,대조조증가19.4μm,불구차이(P>0.05)。<br> 결론:미만형DME환자PRP전,여이TA치료,안전유효,병차우우단순진행PRP치료,가이재기층의원추엄실시。
AIM:To study the effect of posterior sub - Tenon's capsule injection of triamcinolone acetonide ( TA ) in treatment of patients with diffuse diabetic macular edema ( DME) before panretinal photocoagulation ( PRP) . <br> METHODS:Retrospective analysis of the clinical data of 96 cases (96 eyes) with DME treated in our hospital from October 2008 to May 2012, and the patients were divided into the study group and control group, each group with 48 cases ( 48 eyes ) , the control group were only treated with PRP, and for the study group, TA was injected one week before PRP. At 6mo after treatment, best-corrected visual acuity ( BCVA) and retinal thickness changes of two groups were compared, the changes of intraocular pressure in two groups was analyzed. <br> RESULTS:After treatment, two groups were followed up for 6mo, compared with before treatment, the expression of BCVA in control group was reduced, and rise in the study group, with significant difference between the two groups (P<0. 05), and during the follow-up period, IOP change was in the normal range for the two groups, with no the difference (P>0. 05), the study group had foveal thickness reduction of 9. 6μm, the control group was increased by 31. 9μm, with significant difference (P<0. 05), parafoveal thickness in the study group decreased 5μm, significantly increased 22. 1μm in the study group, centre concave surrounding thickness increased 0. 4μm in study group and 19. 4μm for the control group, with no significant difference (P>0. 05).CONCLUSION:TA injection in patients with diffuse DME before PRP is safe and effective, and it is superior to simple PRP therapy, and it can be applied in primary hospital.